Want to join the conversation?
Biopharmaceutical company $AMGN said European Commission (EC) granted marketing authorization for its Kyprolis drug in combination with lenalidomide and dexamethasone for treating adults with multiple myeloma (incurable blood cancer) who have received at least one prior therapy. EC approved Kyprolis based on data from pivotal Phase 3 aspire trial.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?